Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Background: Glucocerebrosidase gene ( GBA ) mutations influence risk and prognosis of Parkinson’s disease (PD), possibly through accumulation of glycosphingolipids, including glucosylceramide (GL-1). Venglustat is a novel, brain penetrant glucosylceramide synthase inhibitor. Objective: Evaluate veng...

Повний опис

Бібліографічні деталі

Автори:	M. Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, Thomas Gasser, Stuart H. Isaacson, Sebastiaan J.M. Gaemers, Pascal Minini, Stéphane Saubadu, Jyoti Sharma, Samantha Walbillic, Roy N. Alcalay, Gary Cutter, Nobutaka Hattori, Günter U. Höglinger, Kenneth Marek, Anthony H.V. Schapira, Clemens R. Scherzer, Tanya Simuni, Nir Giladi, Sergio Pablo Sardi, Tanya Z. Fischer
Формат:	Artigo
Мова:	Inglês
Опубліковано:	SAGE Publishing 2022-02-01
Серія:	Journal of Parkinson’s Disease
Онлайн доступ:	https://doi.org/10.3233/JPD-212714
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!